Protagen Oncimmune Buys Protagen for £4.1M The company said that it plans to use Protagen's assets to further the development and commercialization of its EarlyCDT cancer diagnostics. Protagen, NCT Heidelberg Partner to Predict Immunotherapy Response in Urothelial Cancer The project aims to identify biomarkers for predicting response and adverse events in urothelial carcinoma patients receiving immunotherapy. Protagen, NCT, NEC Partner on Prediction of Immunotherapy Response in Melanoma The parties will use machine learning to develop biomarker models for immunotherapy endpoints, including adverse effects, clinical response, and survival. Protagen Shifting to Focus on Cancer Immunotherapy Premium With a series of recent collaborations in hand, the company is leveraging its experience in autoimmune biomarkers to move into the immunoncology space. Protagen, Gustave Roussy Collaborating on Markers for Immunotherapy Side Effects Under the collaboration, they will use Protagen's SeroTag platform to test cancer immunotherapy patients for markers linked to immune-related adverse events. Feb 2, 2017 Protagen, NCI Partner to Identify Cancer Immunotherapy Biomarkers Jan 20, 2017 Immunovia's Blood-Based Array Test for Lupus Advances in New Study Premium Jan 17, 2017 Protagen, German Cancer Center Collaborate on Immunotherapy Biomarkers Aug 11, 2016 Protagen Licenses Systemic Sclerosis Marker to Inova Jun 15, 2016 Protagen Receives CE Mark for BICD2 Systemic Sclerosis Marker Mar 4, 2016 Protagen Using Protein Array Tech for Drug Target ID; Will Release Autoimmune Marker Panels Premium Feb 12, 2016 Researchers From Protagen, Targos, Elsewhere ID Protein Biomarkers for Prostate Inflammation Dec 11, 2015 Protagen Working With MATURA Consortium to Develop Proteomic Test to Predict Drug Response in RA Premium Nov 12, 2015 Protagen, Mikrogen Ink Lyme Disease Diagnostic Deal Jun 24, 2015 Protagen Obtains ISO Certification Dec 16, 2014 Protagen Closes First Part of Financing Round Nov 21, 2014 Qiagen Makes Move toward Proteomics with Protagen CDx Development Deal Premium Nov 17, 2014 Protagen, Qiagen Collaborate to Advance Development of Protein-based CDx for Autoimmune Diseases Sep 5, 2014 New Products: Biognosys, Protagen Premium Dec 3, 2013 Protagen Signs Biomarker Discovery Deal with Pfizer Jul 2, 2013 Protagen Sells Protein Services Subsidiary in Shift Toward Focus on Dx Development Mar 16, 2012 Protagen and NMI Collaborating on Protein Dx for Cancer and Autoimmune Diseases Premium Mar 16, 2012 Protagen, NMI Developing Assays for Autoimmune Diseases, Cancer Dec 7, 2011 Protagen, Bayer Partner on Biomarkers for Endometriosis Oct 28, 2011 Protagen, Charles River Ink Protein Analysis Services Alliance Load More Breaking News GA4GH Announces 10 New 'Driver' Projects, Including First Pediatric Partner Single-Cell MRD Assay Helps Characterize Cells Surviving Acute Myeloid Leukemia Therapy Research Triangle Institute Partners With GeneDx, Illumina for Expanded Newborn Screening Study Bionano Genomics' Third Chinese OEM Partner Gets NMPA Nod for Sample Prep Product InformedDNA Buys gWell Health, Names New CEO The Scan Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants. Small Study of Gene Editing to Treat Sickle Cell Disease In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms. Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema. Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.